Anupam Rasayan revenue jumps 65% in FY26 as margins slide
Annual revenue growth of 65% masks a contraction in EBITDA margins and an 11% year-on-year drop in Q4 profit.
What's new
- FY26 revenue grew 65% year-on-year.
- EBITDA margins fell from 28% to 23% in FY26.
- Q4 profit after tax dropped 11% compared to the same quarter last year.
Why this matters
Top-line expansion is failing to protect the bottom line as margins compress. The decline in Q4 profit suggests that the company's recent acquisitions and deals are yet to deliver the expected earnings efficiency.
What we're watching
- Whether margins recover in FY27 as the Jayhawk acquisition integrates.
- The impact of the Bliss GVS Pharma deal on future quarterly margins.
- Management's plan to reverse the 11% profit slide seen in Q4.
The full read
Anupam Rasayan posted 65% revenue growth for FY26, but the numbers reveal a thinning bottom line. EBITDA margins dropped from 28% to 23% in the prior year, signaling that the company's aggressive expansion is coming at a cost to profitability. This pressure on margins culminated in an 11% year-on-year decline in Q4 profit after tax. While the company continues to integrate the Jayhawk acquisition and execute its deal with Bliss GVS Pharma, the immediate challenge is the margin compression. The top-line growth is clear, but the earnings quality is under pressure. The next test is whether the company can stabilize its margins in FY27 as these strategic assets begin to contribute more effectively to the bottom line.
Questions answered
- How did Anupam Rasayan perform in FY26?
- The company reported a 65% year-on-year increase in revenue for the full fiscal year. However, EBITDA margins contracted from 28% to 23%.
- What was the trend for profit in the final quarter?
- Profit after tax for Q4 fell 11% compared to the same period in the previous year.
- Are there any new strategic developments in this release?
- The release covers the financial results but references previously disclosed milestones, specifically the Jayhawk acquisition and the Bliss GVS Pharma deal.